Ajanta Pharma USA Inc., based in Bridgewater, New Jersey, is a wholly owned subsidiary of Ajanta Pharma Ltd. Ajanta Pharma is committed to delivering quality generic drugs to patients, through collaboration with its industry partners. Ajanta Pharma is dedicated to superior service, supply chain reliability and flexibility to meet the unique needs to its customers. Since making the strategic decision to enter the US market, our Research and Development (R&D) team began developing a product portfolio of Abbreviated New Drug Application (ANDA) filings with a mix of Immediate-Release, Extended-Release, Delayed-Release, Orally Disintegrating Tablets and Powders.

As on 30th June 2021, Ajanta has 38 ANDA approvals which are commercialised. And we are awaiting US FDA approval for 15 ANDAs. Company plans to file 10-12 ANDAs during the current financial year.

Ajanta Pharma Ltd is a pharmaceutical company with global headquarters in Mumbai, India. Over 7,000+ employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries. The R&D Center houses over 650+ scientists with significant expertise to develop complex formulations in various dosage forms including tablets, capsules, powders, ophthalmic sterile eye drops, ointments and injectables.

Since Ajanta's inception in 1973, we have remained unwavering in our focus and commitment; a credo which has made us one of the fastest growing companies in India and emerging markets. Consistent with the company's heritage, Ajanta Pharma enters the US market with the same focus and commitment.